Once again, Weitz & Luxenberg has been listed by U.S. News & World Report as one of the 2023 Best Law Firms in the United…
Read MoreFirm News: Drugs & Devices: Page 10
Category: Drugs & Devices
FDA Reviewing SGLT2 Inhibitors and Acute Pancreatitis Reports
Updated September 14, 2017. Following reports of acute pancreatitis among people taking a type of diabetes medication, the U.S. Food and Drug Administration (FDA)…
Category: Drugs & Devices
Danielle Gold Speaks on Stryker LFIT V40 Litigation at AAJ Mass Torts Seminar
Danielle Gold, an associate attorney in Weitz & Luxenberg’s Drug and Medical Device Litigation group, will participate in a discussion on Stryker’s LFIT V40…
Category: Drugs & Devices
Onglyza & Kombiglyze XR
Onglyza and Kombiglyze XR are approved for use with diet and exercise to control blood sugar in adults with type 2 diabetes. Results from…
Category: Drugs & Devices
W&L Investigates Rising Costs of Insulin
Weitz & Luxenberg is investigating the pricing of insulin by three major drug companies — Eli Lilly, Novo Nordisk, and Sanofi — following a…
Category: Drugs & Devices
Zimmer Biomet Recalls Comprehensive Reverse Shoulder, Cites High Fracture Rate, says FDA
Weitz & Luxenberg is currently accepting cases from people harmed by a faulty shoulder replacement device made by Zimmer Biomet.The medical device manufacturer issued…